^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-986406
i
Other names: BMS-986406, ONO-7226, BMS986406, BMS 986406, ONO7226, ONO 7226
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, Ono Pharma
Drug class:
ILT-4 inhibitor
Related drugs:
1year
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov)
P1, N=77, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=154 --> 77
Trial completion • Enrollment change • Combination therapy • Metastases
|
Opdivo (nivolumab) • carboplatin • paclitaxel • pemetrexed • BMS-986406
over1year
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov)
P1, N=154, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jul 2026 --> Jul 2024 | Trial primary completion date: Apr 2026 --> Jul 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • carboplatin • paclitaxel • pemetrexed • BMS-986406
over1year
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov)
P1, N=154, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Opdivo (nivolumab) • carboplatin • paclitaxel • pemetrexed • BMS-986406
over2years
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov)
P1, N=154, Recruiting, Bristol-Myers Squibb | N=112 --> 154
Enrollment change • Combination therapy • Metastases
|
Opdivo (nivolumab) • carboplatin • paclitaxel • pemetrexed • BMS-986406
Share via
